title: Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinion.
authors: Department of Pediatrics, New England Medical Center, Tufts University School of Medicine, Boston, Mass 02111, USA. cmeissner@es.nemc.org
authors: H C
authors: HC
authors: Meissner
authors: R C
authors: RC
authors: Welliver
authors: S A
authors: SA
authors: Chartrand
authors: B J
authors: BJ
authors: Law
authors: L E
authors: LE
authors: Weisman
authors: H L
authors: HL
authors: Dorkin
authors: W J
authors: WJ
authors: Rodriguez
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007234:Infant, Premature; D000069455:Palivizumab; D018357:Respiratory Syncytial Virus Infections / Q000517:prevention & control*; D012136:Respiratory Syncytial Viruses / Q000276:immunology*; D012307:Risk Factors
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069455:Palivizumab